Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael A Postow

Showing results (121-130 of 212) with videos related to

Pageof 22
Sort By:
The Oncologist|March 27, 2019
Myocarditis Surveillance in Patients with Advanced Melanoma on Combination Immune Checkpoint Inhibitor Therapy: The Memorial Sloan Kettering Cancer Center ExperienceKatherine Lee Chuy, Evangelos K Oikonomou, Michael A Postow, et al.
Melanoma Research|June 25, 2025
Programmed death ligand-1 PET imaging in patients with melanoma: a pilot studyNeeta Pandit-Taskar, Audrey Mauguen, Denise Frosina, et al.
Cancer Cell|August 15, 2025
Fc-optimized CD40 agonistic antibody elicits tertiary lymphoid structure formation and systemic antitumor immunity in metastatic cancerJuan C Osorio, David A Knorr, Polina Weitzenfeld, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 22, 2015
Improving the Evidence Base for Treating Older Adults With Cancer: American Society of Clinical Oncology StatementArti Hurria, Laura A Levit, William Dale, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 23, 2016
Reply to N. Lowy et al and to J. Dhanda et alArti Hurria, Laura A Levit, William Dale, et al.
Journal for Immunotherapy of Cancer|November 20, 2021
Treatment-free survival over extended follow-up of patients with advanced melanoma treated with immune checkpoint inhibitors in CheckMate 067Meredith M Regan, Charlene M Mantia, Lillian Werner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 21, 2016
Reply to A. Indini et alTroy Z Horvat, Nelly G Adel, Thu-Oanh Dang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 19, 2015
Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer CenterTroy Z Horvat, Nelly G Adel, Thu-Oanh Dang, et al.
Cancer Cell|October 10, 2018
Non-conventional Inhibitory CD4<sup>+</sup>Foxp3<sup>-</sup>PD-1<sup>hi</sup> T Cells as a Biomarker of Immune Checkpoint Blockade ActivityRoberta Zappasodi, Sadna Budhu, Matthew D Hellmann, et al.
The Oncologist|May 11, 2025
Sarcoid-like reactions in patients treated with checkpoint inhibitors for advanced solid tumorsIan Nykaza, Yonina R Murciano-Goroff, Antoine Desilets, et al.
Pageof 22

Showing results (121-130 of 212) with videos related to

Sort By:
Pageof 22
The Oncologist|March 27, 2019
Myocarditis Surveillance in Patients with Advanced Melanoma on Combination Immune Checkpoint Inhibitor Therapy: The Memorial Sloan Kettering Cancer Center ExperienceKatherine Lee Chuy, Evangelos K Oikonomou, Michael A Postow, et al.
Melanoma Research|June 25, 2025
Programmed death ligand-1 PET imaging in patients with melanoma: a pilot studyNeeta Pandit-Taskar, Audrey Mauguen, Denise Frosina, et al.
Cancer Cell|August 15, 2025
Fc-optimized CD40 agonistic antibody elicits tertiary lymphoid structure formation and systemic antitumor immunity in metastatic cancerJuan C Osorio, David A Knorr, Polina Weitzenfeld, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 22, 2015
Improving the Evidence Base for Treating Older Adults With Cancer: American Society of Clinical Oncology StatementArti Hurria, Laura A Levit, William Dale, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 23, 2016
Reply to N. Lowy et al and to J. Dhanda et alArti Hurria, Laura A Levit, William Dale, et al.
Journal for Immunotherapy of Cancer|November 20, 2021
Treatment-free survival over extended follow-up of patients with advanced melanoma treated with immune checkpoint inhibitors in CheckMate 067Meredith M Regan, Charlene M Mantia, Lillian Werner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 21, 2016
Reply to A. Indini et alTroy Z Horvat, Nelly G Adel, Thu-Oanh Dang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 19, 2015
Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer CenterTroy Z Horvat, Nelly G Adel, Thu-Oanh Dang, et al.
Cancer Cell|October 10, 2018
Non-conventional Inhibitory CD4<sup>+</sup>Foxp3<sup>-</sup>PD-1<sup>hi</sup> T Cells as a Biomarker of Immune Checkpoint Blockade ActivityRoberta Zappasodi, Sadna Budhu, Matthew D Hellmann, et al.
The Oncologist|May 11, 2025
Sarcoid-like reactions in patients treated with checkpoint inhibitors for advanced solid tumorsIan Nykaza, Yonina R Murciano-Goroff, Antoine Desilets, et al.
Pageof 22